Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13031578 | 0.81 | ALDH1A1 (0.40) | FPR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30554042 | 0.80 | KDM4E (0.40) | FPR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15335292 | 0.80 | ALPL (0.47) | FPR2KDM4EALDH1A1HDAC6 | |
| SCHEMBL12706154 | 0.79 | LPO (0.42) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL18839106 | 0.79 | MAPT (0.40) | KDM4EALDH1A1MAPT | |
| SCHEMBL28485619 | 0.78 | L3MBTL1 (0.43) | KDM4EALDH1A1HPGDHSD17B10CRHBP | |
| Trifluoroacetic Acid SCHEMBL3580507 | 0.77 | KDM4E (0.39) | FPR2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13263679 | 0.77 | ALPG (0.49) | FPR2KDM4EALDH1A1HDAC6 | |
| SCHEMBL18839661 | 0.77 | L3MBTL1 (0.45) | KDM4EALDH1A1MAPT | |
| SCHEMBL28420219 | 0.77 | KDM4E (0.43) | KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | FPR2 64/4885KDM4E 3447/4885ALDH1A1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.